skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

世界の医薬品産業に関する包括的なニュース配信サービス

Scrip
Scrip(スクリプ)は、インフォーマ・ファーマインテリジェンスが提供するニュース配信サービスの中でも、最も包括的に世界中の医療用医薬品と製薬産業全般に関するニュースを配信するサービスです。

今この瞬間にグローバルな医薬品産業で何が起きているのでしょうか。欧米のメガファーマやバイオベンチャーはどのような戦略を描いているのでしょうか。そして、それらの競争環境が御社のビジネスに与える影響は?

Scripは医薬品の研究開発や臨床試験に関する情報から、ライセンシングやディール活動、薬価政策に関するニュースまで幅広く取材しています。長年に渡り世界の医薬品産業を取材・分析・研究しているジャーナリストとアナリストが、単なる事実の報道ではない、御社の意思決定とビジネスの国際展開に役立つインテリジェンスをお届けします。

医薬品業界に従事される新入社員から経営層まで定番のニュースソースとしてお読みください。実際のScripのページへアクセスしていただくと、ログインせずに各記事の冒頭部分を読むことができます。

このサービスの特徴

無料の最新記事&レポート

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    Claims Stream In Under COVAX No-Fault Compensation Program

    SC2107_compensationclaims_F3YYB6_1200x675

    The WHO indicates that several claim applications have been made under the COVAX no-fault lump-sum compensation program for COVID-19 vaccines. It remains to be seen how the scheme may apply to countries like India, which is also expected to take a call on indemnity to vaccine makers.

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    10 US Approval Decisions To Look Out For In Q3

    SC_2107_lioness_2ATXAHM_1200

    This quarter has already seen a complete response letter for Iterum Therapeutics’ antibiotic sulopenem but a raft of other products are expecting approval decisions from the US Food and Drug Administration in the next three months. With the help of analysts at Biomedtracker, Scrip takes a look at 10 of the more interesting ones.    

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    Quick Listen: Scrip’s Five Must-Know Things

    SC2008_FiveMustKnowThings_1200_Final

    In this week's podcast edition of Five Must-Know Things: vaccine efficacy and the Delta and Delta Plus variants; breakthroughs in CRISPR gene editing and microbiome therapies; and the pandemic’s possible effect on regulatory pathways.

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    Canadian Biotech Progresses COVID-19 Nasal Spray, Claims Promise Against Variants

    SC2106_coronavirusspray_2B9MH55_1200x675

    SaNOtize is to start Phase III trials for its nitric oxide nasal spray for COVID-19 and hopes to enlist volunteers from several countries, including India. The Canadian firm claims initial studies have demonstrated effectiveness across SARS-CoV-2 mutations, with plans afoot to validate it against the spreading Delta variant.

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    Intellia Achieves Gene-Editing Breakthrough With First In Vivo CRISPR Therapy

    IntelliaTherapeuticsheadquartersinCambridgeMassscaled1

    The first use of CRISPR/Cas9 in humans shows promising safety and efficacy against rare disease ATTR, and opens up the possibility of treating many genetic diseases.

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    Quick Listen: Scrip’s Five Must-Know Things

    SC2008_FiveMustKnowThings_1200_Final

    In this week's podcast edition of Five Must-Know Things: a look at pharma CEO pay; Pfizer’s CEO gives the inside track on COVID vaccine development; GSK elaborates on its restructuring and strategic plans; and Kite talks about its cell therapy plans under Gilead. 

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    Fresh Win For AstraZeneca/Merck & Co Pact With Koselugo Approval

    SC2106_euflag_E71W82_1200

    Koselugo (selumetinib) was largely forgotten after failing Phase III trials in thyroid and lung cancer, as well as uveal melanoma, but its approval in Europe for inoperable plexiform neurofibromas in patients with neurofibromatosis type 1, which follows a US approval for the rare condition last year, has breathed new life into the once-lauded MEK 1/2 inhibitor.

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    Quick Listen: Scrip’s Five Must-Know Things

    SC2008_FiveMustKnowThings_1200_Final

    In this week's podcast edition of Scrip's Five Must-Know Things: new developments in the TIGIT field; doctor frustration over Aduhelm guidance; are pediatric COVID vaccines necessary: the battle of the SERDs; and one Indian firm’s plans for lung disease leadership.

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    US Backs Oral COVID-19 Therapies And ‘Next Pandemic’ Drug Discovery With $3.2bn

    FauciTony2021

    Aiming to mimic public-private COVID-19 vaccine success, the US NIH will fund pandemic drug research, including taking candidates up to Phase II.

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    Biogen/Sage’s Zuranolone Data May Not Be Enough For Tough Commercial Landscape

    Depression_703104430_1200x675

    The drug may have enough efficacy for approval, but data fell short of the benchmark seen as necessary for commercial adoption.

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    Novavax’s Latecomer COVID-19 Vaccine Impresses With 90% Efficacy Result

    NovavaxFlag

    Arriving two to three months later than planned, Novavax’s nanoparticle-based vaccine is still a welcome addition to the field, for both rich and poor countries.

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    Quick Listen: Scrip’s Five Must-Know Things

    SC2008_FiveMustKnowThings_1200_Final

    In this week's podcast edition of Five Must-Know Things: a ground-breaking approval for Alzheimer’s in the US; LAG-3 inhibitors and new Keytruda data generate excitement at ASCO; and clinical progress for another COVID-19 vaccine.

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    IQVIA Biotech’s Sockalingam On Clinical Research Virtualization In APAC

    SC2105_Generic_Podcast_Image_1200

    In this audio interview, the head of IQVIA Biotech (Japan-Asia Pacific) talks to Scrip on a range of aspects around digitalization and virtualization of clinical research in the region, including sharply reduced site contracting timelines. He also touches on the digital product launch efforts that are currently a reality in several markets.

  • 世界の薬事規制動向&情報を配信, Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    Drug Pricing eBook

    Tap into expert coverage of the complex world of drug pricing with insights from analysts at Scrip and Pink Sheet. This eBook includes vital information about issues affecting drug pricing for the US, EU, and other global markets, including patient access, regulatory issues, commercial challenges, value-based pricing, and more.

    Topic drug-pricing

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    UK Trial Could Help Pick Best Covid Vaccine Boosters

    UK_Bolton_Vaccination_1200

    Results will be important in fight against new variants, for second-generation vaccines and AstraZeneca’s controversy-hit jab.

医薬品産業専門のジャーナリスト&アナリスト

Editor

Brenda Sandburg

Editor, Senior Editor

New York, USA

Brenda Sandburg

Brenda specializes in

  • Policy and Regulation
  • Biosimilars
  • Biotech
  • Generics
  • Pricing

+39 year(s) experience

Editor

Cathy Kelly

Editor, Senior editor

Washington DC, USA

Cathy Kelly
Management

Denise Peterson

Management, Editor In Chief, Pharma US

Washington DC, USA

Denise Peterson

無料トライアル&お問い合わせ

ニュースサービスでは無料トライアルを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。

新型コロナウイルス感染拡大防止のため在宅勤務を実施しています。お問い合わせの際は下記のフォームまたはメールアドレスをご利用下さい。

Eメール:inquiry.jp@informa.com


オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。

お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。